AngioDynamics is likely to quickly reach its all-time high in a favorable market environment
The high-margin MedTech revenue share increased from 38% to 43%
The MedTech revenue forecast for 2025 has been raised to 14% to 16%
Reading Time: 1 minute
AngioDynamics (ANGO) is undergoing a transformation process and aims to focus on high-growth medical technology markets such as prostate cancer or thrombectomy. The addressable market potential has more than tripled from USD 3 billion in 2021 to USD 10 billion. Exciting is the FDA approval secured last December for NanoKnife, which presents a global revenue opportunity of USD 2.7 billion for the treatment of prostate cancer as the only device for irreversible electroporation (IRE). Electrical impulses can selectively destroy cancer cells while...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
